LPL Financial LLC Buys 35,335 Shares of Codexis, Inc. (NASDAQ:CDXS)

LPL Financial LLC raised its stake in Codexis, Inc. (NASDAQ:CDXS) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 223,995 shares of the biotechnology company’s stock after acquiring an additional 35,335 shares during the period. LPL Financial LLC owned approximately 0.28% of Codexis worth $1,068,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in CDXS. Kingswood Wealth Advisors LLC bought a new stake in shares of Codexis during the 4th quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Codexis during the 4th quarter worth $82,000. Intech Investment Management LLC increased its stake in shares of Codexis by 55.1% during the fourth quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 11,757 shares during the period. Jackson Square Capital LLC bought a new stake in shares of Codexis in the fourth quarter valued at about $210,000. Finally, Monimus Capital Management LP purchased a new stake in Codexis in the fourth quarter worth about $339,000. Institutional investors own 78.54% of the company’s stock.

Codexis Price Performance

Shares of CDXS stock opened at $2.11 on Friday. The company has a market cap of $174.79 million, a P/E ratio of -2.43 and a beta of 2.35. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The stock’s 50-day moving average is $2.93 and its 200 day moving average is $3.85. Codexis, Inc. has a 1-year low of $1.90 and a 1-year high of $6.08.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.09). The company had revenue of $21.46 million for the quarter, compared to analysts’ expectations of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. Research analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.